Current drug targets for Alzheimer's disease treatment

Drug Development Research

Volumn 56, Issue 3, 2002, Pages 267-281

  Lahiri, Debomoy K ^a   Farlow, Martin R ^a   Greig, Nigel H ^b   Sambamurti, Kumar ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

Alzheimer's disease; Amyloid; Anticholinesterases; APP gene; Cholesterol; Cholinergic agents; Cholinomimetic drugs; Donepezil; Estrogen; Exelon; Galantamine; Microtubule associated protein; NSAIDs; Oxidative damage; Phenserine; Vaccine

Indexed keywords

ACETYLCHOLINE; ALPHA SECRETASE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; APOLIPOPROTEIN E; BETA SECRETASE; BIOCHEMICAL MARKER; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GAMMA SECRETASE; HYPOCHOLESTEROLEMIC AGENT; LETEPRINIM; MEMANTINE; MICROTUBULE ASSOCIATED PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENSERINE; PRESENILIN 1; PRESENILIN 2; RIVASTIGMINE; TACRINE; TAU PROTEIN;

ALZHEIMER DISEASE; ANOREXIA; CHOLINERGIC NERVE CELL; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG TARGETING; EARLY DIAGNOSIS; FATIGUE; GENE MUTATION; HORMONAL THERAPY; HUMAN; LIVER TOXICITY; NAUSEA; NEUROFIBRILLARY TANGLE; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; VACCINATION; VOMITING; WEIGHT REDUCTION;

EID: 0036660457     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10081     Document Type: Review

References (124)

1. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C. 2001. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuro-Psychopharmacol Biol Psychiat 25:1341-1357.
2. Arendt T, Bruckner MK, Lange M, Bigl V. 1992. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms. Neurochem Int 21:381-396.
3. Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH. 1986. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 47:263-277.
4. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Sauna J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM. 1999. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 96:15233-15238.
5. Barber K, Mesullam MM, Kraft GA, Klein WL. 1996. Butyrylcholinesterase alters the aggregation state of A-β amyloid. Society Neurosci Abst 22:1172.
6. Bartus RT, Dean RL III, Beer B, Lippa AS. 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-414.
7. Becker RE, Moriearty P, Unni L, Vicari S. 1997. Cholinesterase inhibitors as therapy in Alzheimer's disease:benefit to risk considerations in clinical application. In: Becker R, Giacobini, E, editors. Alzheimer's Disease: from molecular biology to therapy. Boston: Brikhäuser. p 257-266.
8. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG, Go RC, Vekrellis K, Selkoe DJ, Saunders AJ, Tanzi RE. 2000. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 290:2302-2303.
9. Butterfield DA, Drake J, Pocernich C, Castegna A. 2001. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide. Trends Mol Med 7:548-554.
10. Cao X, Sudhof TC. 2001. A transcriptionally active complex of APP with Fe65 and histone cetyltransferase Tip60. Science 293:115-120
11. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitalkis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. 2001. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-676.
12. Chyan YJ, Poeggeler B, Omar RA, Chain DG, Frangione B, Ghiso J. Pappolla MA. 1999. Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J Biol Chem 274:21937-42192.
13. Darvesh S, Grantham DL, Hopldns DA. 1998. Distribution of butyrylcholinesterase in human amygdala and hippocampal formation. J Comp Neurol 393:374-390.
14. Davies P, Maloney AJ. 1976. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:140.
15. De Strooper B, Konig G. 2001. An inflammatory drug prospect. Nature 414:159-160.
16. Dingwall C. 2001. Spotlight on BACE: the secretases as targets for treatment in Alzheilner disease. J Clin Invest 108:1243-1246.
17. Dukic-Stefanovic S, Schinzel B, Biederer P, Munch G. 2001. AGES in brain ageing: AGE-inhibitors as neuroprotective and antidementia drugs? Biogerontology 2:19-34.
18. Enz A, Amstutz R, Boddeke H et al. 1993. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy in Alzheimer's disease. Prog Brain Res 98:431-438.
19. Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, Ronald J, Blangero J, Hutton M, Younkin SG. 2000. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 290:2303-2304.
20. Esler WP, Wolfe MS. 2001. A portrait of Alzheimer secretases: new features and familiar faces. Science 293:1449-1154.
21. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T 2001. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98:5856-5861.
22. Fraser PE, Yu G, Levesque L, Nishimura M, Yang DS, Mount HT, Westaway D, St George-Hyslop PH. 2001. Presenilin function: connections to Alzheimer's disease and signal transduction. Biochem Soc Symp 67:89-100.
23. Friedrich MJ. 2002. Teasing out effects of estrogen on the brain. JAMA 287:29-30.
24. Gao Y, Pimplikar SW. 2001. The gamma-secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus. Proc Natl Acad Sci USA 98:14979-14984.
25. Giacobini E. 2000. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: Giacobini E, editor. Cholinesterases and cholinesterase inhibitors, London: Martin Dunitz. p 181-226.
26. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. 2000. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985-989.
27. Goedert M, Spillantini MG. 2001. Tau gene mutations and neurodegeneration. Biochem Soc Symp 67:59-71.
28. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC. 1987. Characterization and chromosomal localization of a cDNA encoding brain-amyloid of Alzheimer's disease. Science 235:877-880.
29. Goldstein LS. 2001. Kinesin molecular motors: transport pathways, receptors, and human disease. Proc Natl Acad Sci USA 98:6999-7003.
30. Gotz J, Chen F, van Dorpe J, Nitsch BM. 2001. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491-1495.
31. Gozes I. 2001. Neuroprotective peptide drug delivery and development: potential new therapeutics. Trends Neurosci 24:700-705.
32. Greenfield S. 1996. Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Neurochem Int 28:485-490.
33. Greig NH, De Micheli E, Holloway HW, Yu Q-S, Utsuki T, Perry T, Ingram DK, Deutsch J, Lahiri DK, Soncrant TT. 2000a. The experimental Alzheimer drug phenserine: pharmacokinetics and pharmacodynamics in the rat. Acta Neurol Scand 176:74-84.
34. Greig NH, Lahiri Lihiri DK, Sambamurti K. 2000b. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriat (in press).
35. Grossman GT, Stahelin HB, Messina JC, Anand R, Veach J. 2000. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Ger Psych 15:242-247.
36. Guillozet AL, Smiley JF, Mash DC, Mesulam MM. 1997. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 42:909-918.
37. Haass C, De Strooper B. 1999. The presenilins in Alzheimer's disease: proteolysis holds the key. Science 286:916-919.
38. Hardy J. 2001. Genetic dissection of primary neurodegenerative diseases. Biochem Soc Symp 67:51-57.
39. Haroutunian V, Greig NH, Pei XF, Utsuld T, Gluck R, Acevedo LD, Davis KL, Wallace WC. 1997. Pharmacological modulation of Alzheimer's β-amyloid precursor protein levels in the CSF of rats with forebrain cholinergie system lesions. Brain Res Mol Brain Res 46:161-168.
40. Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C. 2001. Oxidation of Aβ and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol Dis 8:792-806.
41. Hebert LE, Beckett LA, Scherr PA, Evans DA. 2001. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alz Dis Assoc Disord 15:169-173.
42. Herrup K, Yang Y. 2001. Pictures in molecular medicine: contemplating Alzheimer's disease as cancer: a loss of cell-cycle control. Trends Mol Med 7:527.
43. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
44. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C, Christie G. 1999. Identification of a Novel Aspartic Protease (Asp 2) as betaSecretase. Mol Cell Neurosci 14:419-427.
45. Imbimbo BP. 2001. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 15:375-390.
46. Int' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH. 2001. Nonsteroidal antiinflammatory drags and the risk of Alzheimer's disease. New Engl J Med 345:1515-1521.
47. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. 2001. Metabolic regulation of brain Abeta by neprilysin. Science 292:1550-1552.
48. Jagust W. 2001. Untangling vascular dementia. Lancet 358:2097-2098.
49. Janus C, Westaway D. 2001. Transgenic mouse models of Alzheimer's disease. Physiol Behav 73:873-886.
50. Kalaria RN. 2001. Advances in molecular genetics and pathology of cerebrovascular disorders. Trends Neurosci 24:392-400.
51. Kim SJ, Park K, Rudkin BB, Dey BR, Sporn MB, Roberts AB. 1994, Nerve growth factor induces transcription of transforming growth factor-beta 1 through a specific promoter elementin PC12 cells. J Biol Chem 269:3739-3744.
52. Lahiri DK, Lewis S, Farlow MR. 1994. Tacrine alters the secretion of the beta-amyloid precurs or protein in cell lines. J Neurosci Res 37:777-787.
53. Lahiri DK, Nall C. 1.995. Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbolester, retinoic acid and interleukin-1. Brain Res Mol Brain Res 32:233-240.
54. Lahiri DK, Robakis NK. 1991. The promote activity of the gene encoding Alzheimer beta amyloid precursor protein (APP) is regulated by two blocks of upstream sequences. Brain Res Mol Brain Res 9:253-257.
55. Lahiri DK, Sambamurti K. 2000. Neurodiagnostics: focus on Alzheimer's Disease. Spect Diagn Relat Tech 10:1-14.
56. Lahiri DK, Farlow MR, Sambamurti K. 1998. The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Mol Brain Res 62:131-140.
57. Lahiri DK, Farlow MR, Hintz N, Utsuki T, Greig NH. 2000a. Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease. Acta Neurol Scand 176:60-67.
58. Lahiri DK, Song W, Ge Y-W. 2000b. Analysis of the 5′-flanking region of the β-amyloid precursor protein gene that contributes to increased promoter activity in differentiated neuronal cells. Mol Brain Res 77:185-198.
59. Lee VM. 2001. Biomedicine. Tauists and beta-aptists united: well almost! Science 293:1446-1447.
60. Lemere CA, Maron R, Selkoe DJ, Weiner HL. 2001. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol 20:705-711.
61. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. 2001. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487-1491.
62. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. 2001. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosei 21:8370-8377.
63. Lippa CF, Schmidt ML, Nee LE, Bird T, Nochlin D, Hulette C, Mori H, Lee VM, Trojanowski JQ. 2000. AMY plaques in familial AD: comparison with sporadic Alzheimer's disease. Neurology 54:100-104.
64. Loring JF, Wen X, Lee JM, Seilhamer J, Somogyi R. 2001. A gene expression profile of Alzheimer's disease. DNA Cell Biol 20:683-695.
65. Luc PV, Wagner JA. 1997. Regulation of the neural-specific gene VGF in PC12 cells. Identification of transcription factors interacting with NGF responsive elements. J Mol Neurosci 8:223-241.
66. Marx J. 2001. Alzheimer's disease. Bad for the heart, bad for the mind? Science 294:508-509.
67. Mattson MP, Barger SW, Furukawa K, Bruce AJ, Wyss-Coray T, Mark RJ, Mucke L. 1997. Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res Brain Res Rev 23:47-61.
68. Mattson MP, Greig NH. 2001. Slowing down cerebral degeneration. BioFutur Oct:51-53.
69. Mesulam M. 2000. Neuroanatomy of cholinesterases in the normal human brain and in Alzheimer's disease. In: Giacobini E, editor. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz. p. 121-136.
70. Moran MA, Mufson EJ, Gomez-Ramos P. 1993. Colocalization of cholinesterases with β amyloid protein in aged and Alzheimer's brains. Acta Neuropathol 85:362-369.
71. Mori T, Paris D, Town T, Rojiani AM, Sparks DL, Delledonne A, Crawford F, Abdullah LI, Humphrey JA, Dickson DW, Mullan MJ. 2001. Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J Neuropathol Exp Neurol 60:778-785.
72. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears S, Booth J, DeVrieze FW, Crook R, Hamshere M, Abraham R, Tunstall N, Rice F, Carty S, Lillystone S, Kehoe P, Rudrasingham V, Jones L, Lovestone S, Perez-Tur J, Williams J, Owen MJ, Hardy J, Goate AM. 2000. Susceptibility locus for Alzheimer's disease on chromosome 10. Science 290:2304-2305.
73. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD, 2000. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283:1571-1577.
74. Neve RL, McPhie DL, Chen Y. 2001. Alzheimer's disease: dysfunction of a signalling pathway mediated by the amyloid precursor protein? Biochem Soc Symp 67:37-50.
75. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. 1992. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304-307.
76. Nordberg A, Darreh-Shori T, Svenson A, Guan Z. 2001. AChE and BuChE activities in CSF of mild AD patients following 12 months of rivastigmine treatment. J Neurol Sci 187: P0144.
77. Pasinetti GM. 2001. Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia. J Neurosci Res 65:471-476.
78. Pinnix I, Musunuru U, Tun H, Sridharan A, Golde T, Eckman C, Ziani-Cherif C, Onstead L, Sambamurti K. 2001. A novel gammasecretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor. J Biol Chem 276:481-487.
79. Poeggeler B, Miravalle L, Zagorski MG, Wisniewski T, Chyan YJ, Zhang Y, Shao H, Bryant-Thomas T, Vidal R, Frangione B, Ghiso J, Pappolla MA. 2001. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide. Biochemistry 40:14995-15001.
80. Purandare N, Burns A, Craig S, Faragher B, Scott K. 2001. Depressive symptoms in patients with Alzheimer's disease. Internat J Geriat Psychiatr 16:960-964.
81. Price DL, Sisodia SS, Borchelt DR. 1998. Genetic neurodegenerative diseases: the human illness and transgenic models. Science 282:1079-1083.
82. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE. 2001. A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8:890-899.
83. Reynish W, Andrieu S, Nourhashemi F, Vellas B. 2001. Nutritional factors and Alzheimer's disease. J Gerontol Series A-Biol Sci Med Sci 56:M675-680.
84. Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, Nilsson LN. 1999. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences. J Biol Chem 274:6421-6431.
85. Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R, et al. 1989. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med 320:14461-14462.
86. Salbaum JM, Weidemann A, Lemarie HG, Masters CL, Beyreuther K. 1988. The promoter of Alzheimer's disease amyloid A4 precursor gene. EMBO J 7:2807-2813.
87. Sambamurti K, Greig NH, Lahiri DK. 2002a. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. NeuroMol Med 1:1-20.
88. Sambamurti K, Hardy J, Refolo LM, Lahiri DK. 2002b. Targeting APP metobolism for the treatment of Alzheimer's disease. Drug Dev Res 56:211-227.
89. Schenk D, Seubert P, Ciccarelli RB. 2001. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol 20:679-681.
90. Selkoe DJ. 2000. The origins of Alzheimer disease: A is for amyloid. JAMA 283:1615-1617.
91. Shastry BS. 1998. Molecular genetics of familial Alzheimer disease. Am J Med Sci 315:266-272.
92. Shaw KTY, Utsuki T, Rogers J, Yu Q-S, Sambamurti K, Brossi A, Ge Y-W, Lahiri DK, Greig NH. 2001. Phenserine regulates translation of β-amyloid precursor mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 98:7605-7610.
93. Simons M, Keller P, Dichgans J, Schulz JB. 2001. Cholesterol and Alzheimer's disease: is there a link? Neurology 57:1089-1093.
94. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, John V, et al. 1999. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402:537-540.
95. Sisodia SS. 2002. Biomedicine. A cargo receptor mystery Apparently solved? Science 295:805-807.
96. Snow AD, Mar H, Nochlin D, Kimata K, Kato M, Suzuki S, Hassell J, Wright TN. 1988. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am J Pathol 133:156-463.
97. Small DH, Michaulson S, Sberna G. 1996. Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Neurochem Int 453-483.
98. Solomon B. 2001. Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease. DNA Cell Biol 20:697-703.
99. Song W, Lahiri DK. 1998. Functional identification of the promoter of the gene encoding the Rhesus monkey beta-amyloid precursor protein. Gene 217:165-176.
100. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. 1998. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat Med 4:822-826.
101. Soto C, Saborio GP, Permanne B. 2000. Inhibiting the conversion of soluble amyloid-beta peptide into abnormally folded amyloidogenic intermediates: relevance for Alzheimer's disease therapy. Acta Neurol Scand 102:90-95 (Suppl 176).
102. Sparks DL. Martin TA. Gross DR. Hunsaker JC 3rd. 2000. Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc Res Tech 50:287-290.
103. Spillantini MG, Goedert M, Crowther RA, Murrell JR, Farlow MR, Ghetti B. 1997. Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci USA 94:4113-4118.
104. St George-Hyslop PH. 2000. Molecular genetics of Alzheimer's disease. Biol Psychiatr 47:183-199.
105. Suo Z, Humphrey J, Kundtz A, Sethi F, Placzek A, Crawford F, Mullan M. 1998. Soluble Alzheimers β-amyloid constricts the cerebral vasculature in vivo. Neurosci Lett 257:770-780.
106. Stropa EG, Gonzalez AM, Chorsky R, Corna RJ, Alvarez J, Bird ED, Baird A. 1990. Basic fibroblast growth factor in Alzheimer's disease. Biochem Biophys Res Commun 171:690-696.
107. Tanzi RE, Bertram L. 2001. New frontiers in Alzheimer's disease genetics. Neuron 32:181-184.
108. Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML., et al. 1987. Armyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235:880-884.
109. Terry RD. 1998. The cytoskeleton in Alzheimer disease. J Neural Transm Suppl 53:1023-1025.
110. Tol J, Roks G, Slooter AJ, van Duijn CM. 1999. Genetic and environmental factors in Alzheimer's disease. Rev Neurol (Paris) 155:S10-S16.
111. Town T, Tan J, Mullan M. 2001. CD40 signaling and Alzheimer's disease pathogenesis. Neurochem Int 39:371-380.
112. Ugen KE, Morgan D. 2001. Alzheimer's disease: molecularly based immunotherapeutics. DNA Cell Biol 20:677-678.
113. Van Eldik LJ. 2001. Glia and Alzheimer's disease. Neurochem Int 39:329-331.
114. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. 1999. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735-741.
115. Vitiello MV, Borson S. 2001. Sleep disturbances in patients with Alzheimer's disease: epidemiology, pathophysiology and treatment. CNS Drugs 15:777-796.
116. Walter J, Schindzielorz A, Hartung B, Haass C. 2000. Phosphorylation of the beta-amyloid precursor protein at the cell surface by ectocasein kinases 1 and 2. J Biol Chem 275:523-529.
117. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. 2001. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212-216.
118. Wolozin B, Kellman W, Rousseau P, Celesia GG, Siegel G. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439-1443.
119. Wong PC, Price DL, Cai H. 2001. The brain's susceptibility to amyloid plaques. Science 293:1434.
120. Yah B, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME. 1999. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402:533-537.
121. Yankner BA, Duffy LK, Kirschner DA. 1990. Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 250:279-282.
122. Younkin SG. 1998. The role of A beta 42 in Alzheimer's disease. J Physiol 92:289-92.
123. Yu C, Kim SH, Ikeuchi T, Xu H, Gasparini L, Wang R, Sisodia SS. 2001. Characterization of a presenilin-mediated APP carboxyl terminal fragment gammaCTFgamma: evidence for distinct mechanisms involved in gamma-secretase processing of the APP and notch 1 transmembrane domains. J Biol Chem 276:43756-43760.
124. Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS, Perry G, Smith MA. 2001. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech Age Dev 123:39-46.